종양학 기반 생체내 CRO 시장 규모, 점유율 및 성장 분석 : 서비스 유형별, 암 유형별, 모델 유형별, 용도별, 최종사용자별, 연구 단계별, 지역별 - 업계 예측(2026-2033년)

Global Oncology Based In-Vivo CRO Market size was valued at USD 1.50 Billion in 2024 and is poised to grow from USD 1.62 Billion in 2025 to USD 3.02 Billion by 2033, growing at a CAGR of 8.08% during the forecast period (2026-2033).

The oncology-based in vivo Contract Research Organization (CRO) market is experiencing significant growth driven by the increasing demand for translational preclinical models that effectively predict clinical outcomes. This evolution in study outsourcing is reshaping the services provided by CROs, which focus on in vivo efficacy, safety, and pharmacology, utilizing patient-derived xenografts and genetically engineered mouse models. Reliable animal data play a crucial role in shortening development timelines and mitigating clinical risks. As precision oncology continues to evolve, the need for complex models intensifies, prompting biotech firms to adopt advanced platforms for validating targeted agents. Additionally, the integration of biomarker-driven trial designs with in vivo studies enhances CRO offerings, enabling earlier decision-making and optimizing oncology pipelines while addressing regulatory demands for translational relevance.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Oncology Based In-Vivo CRO market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Oncology Based In-Vivo CRO Market Segments Analysis

Global oncology based in-vivo CRO market is segmented by service type, cancer type, model type, application, end user, study phase and region. Based on by service type, the market is segmented into preclinical in-vivo oncology studies, pharmacokinetics & pharmacodynamics studies, toxicology studies, biomarker analysis services, imaging & monitoring services, drug efficacy testing services and others. Based on by cancer type, the market is segmented into lung cancer, breast cancer, colorectal cancer, hematological cancers, prostate cancer, liver cancer and others. Based on by model type, the market is segmented into mouse models, rat models, zebrafish models and others. Based on by application, the market is segmented into drug discovery, preclinical development, immuno-oncology research, precision oncology research, cell & gene therapy research and others. Based on by end user, the market is segmented into pharmaceutical companies, biotechnology companies, academic & research institutes, government research organizations and others. Based on by study phase, the market is segmented into early-stage discovery studies, IND-enabling studies and translational research studies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Oncology Based In-Vivo CRO Market

Innovations in immunology within preclinical models, coupled with advancements in product prediction, have enhanced the reliability of in-vivo testing for contract research organizations (CROs) and biopharmaceutical manufacturers. This heightened confidence enables CROs to present a broader array of in-vivo oncology options that align more closely with the goals of clinical research. As a result, CROs are poised to expand their market presence and foster stronger partnerships with biopharmaceutical sponsors through an expanded range of contract studies. This evolution not only supports the growth of outsourced CRO services but also underscores the strategic significance of providing specialized in-vivo oncology testing in a competitive global marketplace.

Restraints in the Global Oncology Based In-Vivo CRO Market

The Global Oncology Based In-Vivo CRO market faces significant challenges due to the intricate web of ethical and regulatory requirements that create an operational strain on these organizations. The need for comprehensive compliance frameworks, expert personnel, and modified facilities to align with varying animal welfare and study oversight standards increases this burden. Disparities across different jurisdictions further complicate matters, leading to greater administrative demands for multinational studies and hindering the harmonization of protocols, which can deter sponsors from exploring certain in vivo models. This complexity raises entry barriers and restricts the speed and adaptability of study designs, ultimately hampering market growth despite the ongoing scientific need for in vivo evaluations.

Market Trends of the Global Oncology Based In-Vivo CRO Market

The Global Oncology Based In-Vivo CRO market is increasingly witnessing a trend towards integrated translational platforms, where service providers are combining in vivo pharmacology, biomarker discovery, and computational modeling. This consolidation is aimed at streamlining oncology candidate selection processes and expediting decision-making. Sponsors are favoring unified data flows, standardized protocols, and multidisciplinary approaches to minimize fragmentation in the transition from discovery to pre-clinical phases. This evolution encourages more sophisticated collaborations and co-development agreements, enabling longer service contracts and fostering strategic alliances. As a result, providers are shifting from transactional models to collaborative partnerships, enhancing translational predictability and ensuring continuity in oncology programs.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Oncology Based In-vivo CRO Market Size by Service Type & CAGR (2026-2033)

• Market Overview
• Preclinical In-vivo Oncology Studies
• Pharmacokinetics & Pharmacodynamics Studies
• Toxicology Studies
• Biomarker Analysis Services
• Imaging & Monitoring Services
• Drug Efficacy Testing Services
• Others

Global Oncology Based In-vivo CRO Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Hematological Cancers
• Prostate Cancer
• Liver Cancer
• Others

Global Oncology Based In-vivo CRO Market Size by Model Type & CAGR (2026-2033)

• Market Overview
• Mouse Models
• Rat Models
• Zebrafish Models
• Others

Global Oncology Based In-vivo CRO Market Size by Application & CAGR (2026-2033)

• Market Overview
• Drug Discovery
• Preclinical Development
• Immuno-oncology Research
• Precision Oncology Research
• Cell & Gene Therapy Research
• Others

Global Oncology Based In-vivo CRO Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical Companies
• Biotechnology Companies
• Academic & Research Institutes
• Government Research Organizations
• Others

Global Oncology Based In-vivo CRO Market Size by Study Phase & CAGR (2026-2033)

• Market Overview
• Early-stage Discovery Studies
• IND-enabling Studies
• Translational Research Studies

Global Oncology Based In-vivo CRO Market Size & CAGR (2026-2033)

• North America (By Service Type, By Cancer Type, By Model Type, By Application, By End User, By Study Phase)
  • US
  • Canada
• Europe (By Service Type, By Cancer Type, By Model Type, By Application, By End User, By Study Phase)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (By Service Type, By Cancer Type, By Model Type, By Application, By End User, By Study Phase)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (By Service Type, By Cancer Type, By Model Type, By Application, By End User, By Study Phase)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (By Service Type, By Cancer Type, By Model Type, By Application, By End User, By Study Phase)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Charles River Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Labcorp Drug Development
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmaron
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Crown Bioscience
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taconic Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• The Jackson Laboratory
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Champions Oncology
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncodesign Services
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parexel International
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inotiv
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Covance
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Discovery
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MBL International
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Biolabs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Xentech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations